AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $223.75, giving the company a market capitalization of 395.75B. It carries a P/E multiple of 166.58 and pays a dividend yield of 3.0%.
As of 2026-01-27, AbbVie(ABBV) stock has fluctuated between $220.08 and $226.86. The current price stands at $223.75, placing the stock +1.7% above today's low and -1.4% off the high.
The AbbVie(ABBV)'s current trading volume is 5.75M, compared to an average daily volume of 7.17M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
AbbVie (NYSE:ABBV) has agreed a three year deal with the Trump administration to cut US drug prices and invest $100b in US based R&D, manufacturing, and patient...
Citi lowered the firm’s price target on AbbVie (ABBV) to $230 from $235 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma gro...
It doesn't look like the company will end up in the arms of an acquirer soon, after all. Monday was generally a good day for the stock market; nevertheless, so...
Analyst ratings
63%
of 32 ratingsMore ABBV News
These stocks offer highly attractive dividends and staying power. Country music singer Willie Nelson was a relatively young 48 when he released a song with the...
(RTTNews) - Merck & Co Inc. (MRK) is no longer in discussions to acquire biotech company Revolution Medicines, according to a report from the Wall Street Journa...
In mid-January 2026, AbbVie reported positive Phase 3 results for its bispecific antibody epcoritamab in relapsed/refractory diffuse large B-cell lymphoma, and...
West Pharmaceutical Services (NYSE:WST) has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On Body Delivery System to AbbVie. The d...
Advertisement Phase 3 lymphoma data puts AbbVie (ABBV) oncology in focus AbbVie (ABBV) is drawing fresh attention after reporting Phase 3 results for epcorita...
AbbVie (NYSE:ABBV) reported positive Phase 3 EPCORE DLBCL-1 results for epcoritamab as a monotherapy in relapsed or refractory diffuse large B-cell lymphoma. T...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.